# Cancer cachexia in STK11/LKB1-mutated non-small cell lung cancer is dependent on tumor-secreted GDF15

**Authors:** Jinhai Yu, Tong Guo, Arun Gupta, Ernesto M. Llano, Thomas Salisbury, Naureen Wajahat, Dianne Zhao, Sean Slater, Qing Deng, Esra A. Akbay, Beverly A. Rothermel, John M. Shelton, Bret M. Evers, Zhidan Wu, Iphigenia Tzameli, Evanthia Pashos, James Kim, John D. Minna, Puneeth Iyengar, Rodney E. Infante

PMC · DOI: 10.1038/s41467-026-68702-y · 2026-01-30

## TL;DR

This study shows that tumors with STK11/LKB1 mutations cause cachexia by secreting GDF15, a cytokine that leads to weight and muscle loss in lung cancer patients.

## Contribution

The study identifies tumor-derived GDF15 as a key driver of cachexia in STK11/LKB1-mutated non-small cell lung cancer.

## Key findings

- Tumor cell-derived GDF15 levels are elevated in mice with STK11/LKB1-mutant NSCLC.
- Blocking GDF15 prevents cachexia symptoms like weight and muscle loss in these models.
- Restoring STK11/LKB1 reduces GDF15 and rescues the cachexia phenotype.

## Abstract

Cachexia is a wasting syndrome involving adipose, muscle, and body weight loss in cancer patients. Tumor loss-of-function mutations in STK11/LKB1, a regulator of AMP-activated protein kinase, induce cancer cachexia (CC) in preclinical models and are linked to weight loss in non-small cell lung cancer (NSCLC) patients. This study examines the role of the integrated stress response (ISR) cytokine growth differentiation factor 15 (GDF15) in regulating cachexia using patient-derived and engineered STK11/LKB1-mutant NSCLC lines. Tumor cell-derived serum GDF15 levels are elevated in mice bearing these tumors. Treatment with a GDF15-neutralizing antibody or silencing GDF15 from tumor cells prevents adipose/muscle loss, strength decline, and weight reduction, identifying tumors cells as the GDF15 source. Restoring wild-type STK11/LKB1 in NSCLC lines with endogenous STK11/LKB1 loss reverses the ISR and reduces GDF15 expression rescuing the cachexia phenotype. Collectively, these findings implicate tumor-derived GDF15 as a key mediator and therapeutic target in STK11/LKB1-mutant NSCLC-associated cachexia.

GDF15 has been associated with cancer-associated cachexia. Here, the authors show that STK11/LKB1 loss-of-function mutations in non-small cell lung cancer result in an exaggerated integrated stress response culminating in the tumor cell secretion of the cytokine GDF15 promoting cachexia.

## Linked entities

- **Genes:** STK11 (serine/threonine kinase 11) [NCBI Gene 6794], STK11 (serine/threonine kinase 11) [NCBI Gene 6794]
- **Proteins:** GDF15 (growth differentiation factor 15)
- **Diseases:** non-small cell lung cancer (MONDO:0005233)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** STK11 (serine/threonine kinase 11) [NCBI Gene 6794] {aka LKB1, PJS, hLKB1}, GDF15 (growth differentiation factor 15) [NCBI Gene 9518] {aka GDF-15, HG, MIC-1, MIC1, NAG-1, PDF}
- **Diseases:** decline (MESH:D060825), weight loss (MESH:D015431), Cachexia (MESH:D002100), adipose/muscle loss (MESH:D009135), CC (MESH:D009369), wasting syndrome (MESH:D019282), NSCLC (MESH:D002289)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12960653/full.md

---
Source: https://tomesphere.com/paper/PMC12960653